Literature DB >> 21199003

Comparative analysis of pyrosequencing and QMC-PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection.

Salih Ibrahem1, Rashmi Seth, Brendan O'Sullivan, Wakkas Fadhil, Philippe Taniere, Mohammad Ilyas.   

Abstract

Mutation detection is important in cancer management. Several methods are available of which high resolution melting (HRM) analysis and pyrosequencing are the most versatile. We undertook a comparative analysis of these techniques. The methods are: To compare the limit of detection (LOD), mutations in KRAS (codon 12/13 hotspot) and BRAF (V600E hotspot) were tested. DNA mixtures containing mutant alleles at a frequency of around 25%/12.5%/6%/3%/ 1.5%/0.8% were analysed. To compare frequency of mutation detection, 22 DNA samples (nine high quality samples from cell lines, 13 low quality samples from formalin-fixed paraffin-embedded tissue) were tested for three hotspots in KRAS (codons 12/13, 61 and 146) and two hotspots in BRAF (V600E and exon 11). HRM analysis of KRAS (codon12/13) and BRAF (V600E) showed that 3% and 1.5% mutant alleles respectively could be reliably detected whilst pyrosequencing reliably detected 6% mutant alleles in each case. Of 110 tests performed on 22 DNA samples, in 109 cases HRM and pyrosequencing gave identical results. Two of the samples tested had previously been called as wild type for KRAS by direct Sanger sequencing but were found to be mutant by both HRM and pyrosequencing. Both HRM and pyrosequencing can detect small numbers of mutant alleles although HRM has a lower limit of detection. Both are suitable for use in mutation detection and are both more sensitive than Sanger sequencing.
© 2010 The Authors. International Journal of Experimental Pathology © 2010 International Journal of Experimental Pathology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21199003      PMCID: PMC3010548          DOI: 10.1111/j.1365-2613.2010.00733.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  25 in total

1.  Nearest-neighbor thermodynamics and NMR of DNA sequences with internal A.A, C.C, G.G, and T.T mismatches.

Authors:  N Peyret; P A Seneviratne; H T Allawi; J SantaLucia
Journal:  Biochemistry       Date:  1999-03-23       Impact factor: 3.162

2.  Gel-based nonradioactive single-strand conformational polymorphism and mutation detection: limitations and solutions.

Authors:  Vibhuti Gupta; Reetakshi Arora; Anand Ranjan; Narendra K Bairwa; Dheeraj K Malhotra; P T Udhayasuriyan; Anjana Saha; Ramesh Bamezai
Journal:  Methods Mol Biol       Date:  2005

3.  Discovery and identification of sequence polymorphisms and mutations with MALDI-TOF MS.

Authors:  Dirk van den Boom; Mathias Ehrich
Journal:  Methods Mol Biol       Date:  2007

4.  Quick-multiplex-consensus (QMC)-PCR followed by high-resolution melting: a simple and robust method for mutation detection in formalin-fixed paraffin-embedded tissue.

Authors:  Wakkas Fadhil; Salih Ibrahem; Rashmi Seth; Mohammad Ilyas
Journal:  J Clin Pathol       Date:  2010-02       Impact factor: 3.411

5.  Colorectal cancer: mutations in a signalling pathway.

Authors:  D Williams Parsons; Tian-Li Wang; Yardena Samuels; Alberto Bardelli; Jordan M Cummins; Laura DeLong; Natalie Silliman; Janine Ptak; Steve Szabo; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Christoph Lengauer; Victor E Velculescu
Journal:  Nature       Date:  2005-08-11       Impact factor: 49.962

6.  Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck.

Authors:  Jong Woo Lee; Young Hwa Soung; Su Young Kim; Hyo Kyung Nam; Won Sang Park; Suk Woo Nam; Min Sik Kim; Dong Il Sun; Youn Soo Lee; Ja June Jang; Jung Young Lee; Nam Jin Yoo; Sug Hyung Lee
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

Review 7.  Genetic pathways in colorectal and other cancers.

Authors:  M Ilyas; J Straub; I P Tomlinson; W F Bodmer
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

8.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Authors:  Astrid Lièvre; Jean-Baptiste Bachet; Valérie Boige; Anne Cayre; Delphine Le Corre; Emmanuel Buc; Marc Ychou; Olivier Bouché; Bruno Landi; Christophe Louvet; Thierry André; Fréderic Bibeau; Marie-Danièle Diebold; Philippe Rougier; Michel Ducreux; Gorana Tomasic; Jean-François Emile; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

9.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Authors:  David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

10.  A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.

Authors:  Pasi A Jänne; Ana M Borras; Yanan Kuang; Andrew M Rogers; Victoria A Joshi; Hema Liyanage; Neal Lindeman; Jeffrey C Lee; Balazs Halmos; Elizabeth A Maher; Robert J Distel; Matthew Meyerson; Bruce E Johnson
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

View more
  10 in total

1.  A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer.

Authors:  Claudia Martinuzzi; Lorenza Pastorino; Virginia Andreotti; Anna Garuti; Michele Minuto; Roberto Fiocca; Giovanna Bianchi-Scarrà; Paola Ghiorzo; Federica Grillo; Luca Mastracci
Journal:  Endocrine       Date:  2015-08-22       Impact factor: 3.633

Review 2.  KRAS mutation testing in metastatic colorectal cancer.

Authors:  Cong Tan; Xiang Du
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

3.  KRAS Testing: A Tool for the Implementation of Personalized Medicine.

Authors:  Rodney E Shackelford; Nicholas A Whitling; Patricia McNab; Shanker Japa; Domenico Coppola
Journal:  Genes Cancer       Date:  2012-07

4.  Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis.

Authors:  Shanxiang Shen; Dahui Qin
Journal:  Diagn Pathol       Date:  2012-05-28       Impact factor: 2.644

5.  KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues.

Authors:  Jérome Solassol; Jeanne Ramos; Evelyne Crapez; Majda Saifi; Alain Mangé; Evelyne Vianès; Pierre-Jean Lamy; Valérie Costes; Thierry Maudelonde
Journal:  Int J Mol Sci       Date:  2011-05-17       Impact factor: 5.923

6.  Mutation scanning of peach floral genes.

Authors:  Yihua Chen; H Dayton Wilde
Journal:  BMC Plant Biol       Date:  2011-05-23       Impact factor: 4.215

Review 7.  BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.

Authors:  Francesco Spagnolo; Paola Ghiorzo; Laura Orgiano; Lorenza Pastorino; Virginia Picasso; Elena Tornari; Vincenzo Ottaviano; Paola Queirolo
Journal:  Onco Targets Ther       Date:  2015-01-16       Impact factor: 4.147

8.  Evaluation of droplet digital PCR and next generation sequencing for characterizing DNA reference material for KRAS mutation detection.

Authors:  Lianhua Dong; Shangjun Wang; Boqiang Fu; Jing Wang
Journal:  Sci Rep       Date:  2018-11-30       Impact factor: 4.379

9.  Detection of BRAF(V600E) Mutations in Papillary Thyroid Carcinomas by Peptide Nucleic Acid Clamp Real-Time PCR: A Comparison with Direct Sequencing.

Authors:  Dongjun Jeong; Yujun Jeong; Sungche Lee; Hyeran Lee; Wanju Lee; Hyungjoo Kim; Doosan Park; Soyoung Park; Wenxia Mu; Hyun-Deuk Cho; Mee-Hye Oh; Sung Soo Lee; Seung-Ha Yang; Chang-Jin Kim
Journal:  Korean J Pathol       Date:  2012-02-23

Review 10.  RAS testing in metastatic colorectal cancer: advances in Europe.

Authors:  J Han J M Van Krieken; Etienne Rouleau; Marjolijn J L Ligtenberg; Nicola Normanno; Scott D Patterson; Andreas Jung
Journal:  Virchows Arch       Date:  2015-11-16       Impact factor: 4.064

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.